-
-
In this article, Adams and Nelson integrate results from several disparate fields to advance the concept that autoimmune conditions resemble host vs graft disease and that the graft in many cases may be fetal or maternal cells that lodge in the host, namely the mother or fetus, respectively.
-
Changes in screening, endocervical sampling, nomenclature, and improvements in treatment likely explain the increased in situ cervical SCC incidence in white and black women. Increasing AIS incidence over the past 20 years in white women has not yet translated into a decrease in invasive AC incidence.
-
Hormonal replacement therapy after breast canceris It Safe? (HABITS) began in May 1997, to compare breast cancer survivors treated for at least 2 years with hormone therapy with treatment other than hormones. By September 2003, a total of 434 women had been randomized and, in December 2003, the steering committee of the HABITS study made the decision to stop the trial because there were 26 women in the treated group and 7 in the non-treated group with new breast cancer diagnoses.
-
In February, the FDA approved a new monoclonal antibody for the treatment of metastatic colorectal cancer.
-
Long-term treatment with aspirin is associated with a progressive diminution in platelet sensitivity to the drug.
-
The common and increasing practice of opioid treatment for chronic pain is reviewed. Randomized trials support this therapy, however the risk benefit decision is complicated by new evidence of hazards making this practice more difficult.
-
The use of serum procalcitonin helps to differentiate bacterial from viral lower respiratory infections and may reduce the use of unnecessary antibiotics.
-
-
